Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Version 2 2023-06-15, 15:27
Version 1 2023-06-08, 11:22
media
posted on 2023-06-15, 15:27 authored by Adis Journals on behalf of:, Amy S. Paller, Carsten Flohr, Lawrence Eichenfield, Alan Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger<p> </p>
<p><strong>Article full text</strong></p>
<p><br></p>
<p> The above Video Abstract represents the opinions of the <strong>authors</strong>. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite). </p>
Funding
Eli Lilly
History
Related Materials
- 1.
